H uman prion diseases, including Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker disease (GSS), are transmissible and genetic diseases, and involve predominantly the central nervous system (CNS), which shows spongiform changes and abnormal prion protein (PrP) deposits. Some patients with familial and sporadic CJD (sCJD) and GSS show fasciculation, areflexia, glove and stocking type sensory disturbance, and amyotrophy, implying the presence of peripheral neuropathy or motor neuronopathy. [1] [2] [3] [4] [5] [6] [7] Electrophysiological and histological studies supported these clinical signs or subclinical peripheral involvement, and indicated the presence of demyelinating or axonal neuropathy, or loss of anterior horn cells in the spinal cord in human prion diseases. 1-4 8-10 However, PrP deposition in the peripheral nervous system (PNS) has not been fully explored in previous studies. 1-4 8-10 In addition, it remains unclear whether peripheral neuropathy is correlated with abnormal PrP deposition in the PNS of patients with CJD and GSS. In the present study, we carried out immunohistochemical and western blotting analyses of PrP in the PNS in sCJD, dural graft associated CJD (dCJD), and GSS, and we discuss the mechanisms of the PNS involvement in human prion diseases.
METHODS

Patients
We studied eight patients with necropsy confirmed prion diseases: three with sCJD, two with dCJD, 11 12 one with GSS with a PrP P102L mutation (GSS102), and two with a PrP P105L mutation (GSS105) (table 1). One patient (patient 3) with sCJD was an atypical case as PrP plaques were detected in the CNS. 13 Patient 3 presented clinically with dementia, parkinsonism, and pyramidal signs, but no paroxysmal periodic discharges on EEG. 13 In addition, patient 3 showed myokymia, hyporeflexia in the lower extremities, and decreased nerve conduction velocities without conduction block, indicating the presence of peripheral neuropathy. Of the two patients with dCJD, 11 12 one (patient 5) had atypical clinicopathological features showing PrP plaque formation in the brain, 11 but had no evidence of peripheral neuropathy. Patient 6 presented classic clinicopathological manifestations of GSS102, including progressive ataxia and dementia, and also showed areflexia in the lower extremities and painful dysaesthesia. 5 The other patients had no clinical signs of peripheral neuropathy.
None of the patients with sCJD or dCJD had mutations in the PrP gene. With regard to polymorphic sites in the PrP gene, codon 129 was methionine/valine in only two cases of GSS105 (patients 7 and 8), 14 and the other patients were homozygous for methionine. All patients were homozygous for glutamic acid in codon 219. The patients with sCJD and dCJD showed a type 1 pattern on western blotting analyses of the protease K resistant PrP (PrP Sc ) in the brain.
Neuropathology
Spinal cords, dorsal root ganglia, spinal roots at several levels, peripheral nerves (mainly sciatic and femoral), and quadriceps femoris muscles were sampled at necropsy. Sections from the PNS were stained by routine techniques, including Klüver-Barrera and Bodian. The sural nerve of patient 3 was embedded in Epon and stained with toluidine blue; teased fibres were also analysed in the sural nerve.
PrP immunohistochemistry
Immunohistochemical studies to detect PrP deposits were carried out using a mouse monoclonal antibody 3F4 (Senetek, Maryland Heights, Missouri, USA; 1:500) after hydrolytic autoclaving of formalin fixed, paraffin embedded sections 8 mm thick. 15 The same specimens as were examined morphologically were studied by PrP immunohistochemistry. 3F4 is a well characterised antibody that recognises an epitope corresponding to amino acids 109 to 112 of human PrP. 16 To confirm specificity of the immunohistochemical reaction, an antigen absorption test was carried out simultaneously using a peptide of 106-115 of human PrP. From patient 3, the femoral nerve was examined for PrP immunohistochemistry. In addition, we used another antiPrP antibody, anti-PrP-95, which recognises residues 95 to 108 of PrP 17 ; the results of PrP immunohistochemistry were shared by both 3F4 and anti-PrP-95.
Western blotting analysis
The dorsal root ganglia tissues from patients 1, 4, and 5, and the femoral nerve and quadriceps femoris muscle tissues from patients 3 and 5 were homogenised by a procedure including a collagenase digestion step to improve detection of PrP Sc , 18 and western blotting analysis of PrP Sc was undertaken with 3F4. 19 
RESULTS
Neuropathology
No neuronal loss or histological abnormalities were observed in any PNS tissues from patients 1, 2, or 4-8, or in the femoral nerve from patient 3. The sural nerve from patient 3 showed no apparent loss of myelinated fibres, but demyelination was seen in 12% of all the teased fibres.
PrP immunohistochemistry
The results of PrP immunohistochemistry are shown in table 2.
Spinal cord
Granular PrP deposits were observed in the posterior horns of the spinal cords, particularly in the substantia gelantinosa, of all patients with sCJD and dCJD (patients 1 to 5), and of one with GSS102 (patient 6) (fig 1, panels A and B). There were no granular deposits of PrP in the spinal cords of two subjects with GSS105 (patients 7 and 8). Only patient 6 with GSS102 and patient 8 with GSS105 showed a few PrP positive plaques in the spinal posterior horns (fig 1) , as reported previously. 5 
Dorsal root ganglia
Granular PrP deposits were detected inside and on the cell surfaces of some dorsal root ganglia neurones in one of two sCJD patients examined (patient 2), and in both of the dCJD cases (patients 4 and 5) (fig 2) . Patient 1 with sCJD, patient 6 with GSS102, and patients 7 and 8 with GSS105 showed no PrP deposits in the dorsal root ganglia.
Spinal roots
Patients 2, 4, and 5-who had PrP deposits in dorsal root ganglia-showed PrP immunoreactivity in some of the spinal roots ( fig 3A) . No PrP deposits were detected in the spinal roots in the patients who showed no PrP deposits in the dorsal root ganglia.
Peripheral nerves
PrP was detected in the peripheral nerves, particularly in the axons of some nerves, from patients 4 and 5 ( fig 3B) . Patients 4 and 5 also showed PrP deposition in the dorsal root ganglia 
dCJD, dural graft associated Creutzfeldt-Jakob disease; GSS, Gerstmann-Sträussler-Sheinker disease; GSS102, GSS with a P102L mutation; GSS105, GSS with a P105L mutation; NE, not examined; PH, posterior horn; sCJD, sporadic Creutzfeldt-Jakob disease.
and the spinal roots. Patients 3 and 6 with clinical signs of peripheral neuropathy showed no PrP deposits in the peripheral nerves.
Muscles
None of the muscles examined from patients 1, 3, 5, and 8 showed PrP immunoreactivity.
Western blotting analysis PrP Sc with a type 1 pattern was detected on western blotting analysis of the dorsal root ganglia, and was seen at a very low level in the peripheral nerve from patient 5 with dCJD, but not in the others (fig 4) . The femoral nerve and quadriceps femoris muscle from patient 3 showed no PrP Sc positive bands (data not shown).
DISCUSSION
Our immunohistochemical studies indicated that PrP deposition occurred in the dorsal root ganglia and peripheral nerves in sCJD and dCJD. Further, western blotting analysis revealed PrP Sc in the dorsal root ganglia and the peripheral nerves in dCJD.
Extensive accumulation of PrP Sc in the dorsal root ganglia and autonomic ganglia has been reported in variant CJD (vCJD). [20] [21] [22] In non-iatrogenic CJD, some immunohistochemical studies have revealed PrP deposits in the PNS. 21 23 24 A patient with possibly familial CJD showed PrP immunoreactivity in the posterior root nerve fibres in an adaxonal location, although western blotting analysis was not undertaken in this case. 23 In a valine homozygous type-1 (VV1) case of sporadic CJD, linear PrP deposits were detected in the posterior roots and along nerve fibres of both myelinated and unmyelinated fibres in the sciatic and peroneal nerves. 24 However, western blotting analysis showed the absence of PrP Sc in this VV1 case of sCJD. 24 With regard to sCJD patients except for VV1 cases, three of six patients showed PrP deposits in the dorsal root ganglia, while no PrP deposition has been found in the peripheral nerves of any patients. 21 Our results support those of previous reports indicating the presence of PrP deposition in the dorsal root ganglia and peripheral nerves in sCJD. 21 24 However, patient 2 in the present study is the first case of methionine homozygous type-1 (MM1) sCJD showing PrP deposits in the PNS, because the previous report did not refer to the PrP phenotypes of the sCJD patients. 21 There was no significant correlation between the duration of the clinical course and the presence of PrP deposits.
Our results indicated a novel finding regarding the presence of PrP Sc in the dorsal root ganglia and peripheral nerves in dCJD. For iatrogenic CJD, PrP deposits have been reported only in the spinal cords of growth hormone related cases and of a patient with dCJD, but not in the PNS. 25 26 Another earlier study showed no PrP Sc deposits in the dorsal root ganglia or the peripheral nerves of a patient with growth hormone related CJD. 21 With regard to GSS (GSS102 and GSS105), no PrP deposits were found in the dorsal root ganglia or nerves in the present study, although the posterior horns of the spinal cord were affected by PrP. 5 14 Our results suggest that there are differences in PrP accumulation in the PNS between CJD and GSS. In skeletal muscles, we found no PrP immunoreactivity or PrP Sc accumulation by western blotting analysis. These results differ from those of a recent report, which showed the presence of PrP Sc in skeletal muscle from eight of 32 patients with sCJD. 27 However, our procedure of PrP Sc analysis with collagenase digestion of samples 18 was different from the one in this previous study which used precipitation with phosphotungstic acid, 27 and our negative results were limited to only four patients-two with sCJD, one with dCJD, and one with GSS105.
PrP deposition is observed in the PNS in natural 28 29 and experimental scrapie, [30] [31] [32] bovine spongiform encephalitis, 33 and variant CJD (vCJD). [20] [21] [22] These previous studies suggest that the PNS can be a neural pathway to the CNS following oral exposure to a prion agent. The strong PrP immunopositivity (consisting of PrP Sc ) of the autonomic and dorsal root ganglia in vCJD may also support a peripheral pathogenesis. [20] [21] [22] However, our results showed PrP Sc deposits in the PNS in dCJD. dCJD might be caused by direct attachment of contaminated cadaveric dura mater to the brain surface, because some patients with dCJD are associated with initial clinical manifestations 12 or abnormalities on magnetic resonance imaging in the dura mater grafted sites (Satoh T, personal communication). These findings suggest that PrP deposits in the PNS do not necessarily provide evidence of peripheral pathogenesis in human prion diseases.
Our results also imply that the PrP deposits in the PNS are not necessarily correlated with clinical presentations of peripheral neuropathy in CJD. In the present study, two patients-patient 3 with sCJD and patient 6 with GSS102-presented with clinical manifestations suggesting involvement of the PNS. Patient 6 had dysaesthesia and areflexia in the lower extremities, which could have reflected involvement of the posterior horn with PrP deposits. Patient 3 showed myokymia, hyporeflexia in the lower extremities, decreased conduction velocities in nerve conduction studies, and some demyelination in the teased fibres. Nerve conduction studies in some CJD patients showed decreases in conduction velocity, 1-3 6 8 multifocal conduction block, 1 low occurrence of F waves, 7 abnormalities of sensory evoked potentials, 7 diminished compound muscle action potential and sensory nerve action potential, and prolonged distal latency. 2 Fibrillation, fasciculation, and polyphasic motor unit potentials have also been reported in electromyograms in patients with CJD. 1 8 The results of histological studies have supported these electrophysiological abnormalities in only a few patients. 1 3 8 In addition, no PrP immunoreactivity was detected in peripheral nerves from CJD patients with histologically confirmed demyelination, which was lanes 1 and 2) . In patient 5 with dCJD, the DRG tissue showed significant immunoreactivity with 3F4 (lane 3), and the peripheral nerve showed faint immunoreactivity (lane 4). The skeletal muscle from patient 5 showed no immunoreactivity (lane 5).
